Psy184 - Hta and Reimbursement Considerations for Rare Diseases in European Markets: What Are the Implications for Manufacturers?s?
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2758
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV